[Cetuximab improved the poor performance status of a colorectal cancer patient].
A 60-year-old man with unresectable colon cancer required treatment for hydronephrosis, acute cholecystitis, and obstructive jaundice before chemotherapy. His performance status (PS) gradually deteriorated to PS 4. Cetuximab monotherapy was initiated instead of intensive chemotherapy. His general condition improved and mFOLFOX7 therapy was then continued in addition to cetuximab. A computed tomography (CT) scan after 6 months of chemotherapy revealed a partial response (PR). Cetuximab monotherapy may contribute to the treatment of patients with a poor PS.
Dept. of Surgery, Kansai Rosai Hospital.
Hideki
H
Sakisaka
Takeshi
T
Kato
Yoshinori
Y
Kagawa
Tomo
T
Ishida
Yasufumi
Y
Sato
Yoshihiro
Y
Morimoto
Katsunori
K
Matsushita
Tadayoshi
T
Hashimoto
Hiroki
H
Kusama
Kei
K
Kimura
Yoshiteru
Y
Katsura
Kanae
K
Nitta
Masatsugu
M
Okishiro
Atsushi
A
Takeno
Shin
S
Nakahira
Hirokazu
H
Taniguchi
Chiyomi
C
Egawa
Yutaka
Y
Takeda
Shigeyuki
S
Tamura
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab